Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Otsuka reports positive data from schizophrenia drug trial

Otsuka reports positive data from schizophrenia drug trial

20th April 2015

Otsuka has reported positive data from a new trial demonstrating the effectiveness of its drug brexpiprazole in the treatment of adult patients with schizophrenia.

The study evaluated the efficacy and tolerability of brexpiprazole in adult patients with an acute exacerbation of schizophrenia and has been published in the American Journal of Psychiatry. The results showed that the drug can offer significant benefits compared to placebo.

Brexpiprazole is a serotonin-dopamine activity modulator developed in partnership between Otsuka and Lundbeck.

Its development could potentially lead to a new treatment avenue for the difficult-to-treat mental disorder, which affects at least 21 million people worldwide.

Dr Christoph Correll, professor of psychiatry at the Hofstra North Shore LIJ School of Medicine, said: "It is important for clinicians and patients to have a range of treatment options to manage symptoms, and the publication of this data helps increase awareness of the potential of brexpiprazole in this patient population."ADNFCR-8000103-ID-801784191-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.